PTSD develops when the brain's fear-processing circuits fail to recalibrate after trauma. The amygdala, responsible for threat detection, becomes hyperactive, while the prefrontal cortex, which normally modulates fear responses, loses regulatory control. Research shows that approximately 7-8% of the U.S. population will experience PTSD at some point, with rates reaching 11-20% among combat veterans.
This neurological imbalance triggers a cascade of stress hormones, including cortisol and norepinephrine, that keep the body in a perpetual fight-or-flight state. Over time, chronic stress hormone elevation damages hippocampal neurons responsible for contextualizing memories, making it impossible to distinguish past danger from present safety.
Glutamate signaling, the brain's primary excitatory neurotransmitter system, becomes dysregulated in PTSD. Excessive glutamate activity strengthens fear memory consolidation while impairing the formation of new, safety-associated neural pathways, which is precisely why traditional talk therapy alone often falls short for treatment-resistant cases.
